Articles à la Une

In his report, titled “Much More Than a Market” which was published in April, Enrico Letta states that “competitiveness means prosperity for our citizens”. Indeed, ensuring […]

In two weeks, on March 19th, the environmental, public health and food safety (ENVI) committee of the European Parliament will vote on the reform of the pharmaceutical legislation. This proposal put forward by the European Commission in April 2023 has been the centre-stage of a deeply rooted divide in the European Parliament. It opposes Members of the European Parliament wanting to find a short term solution at EU level for the accessibility of medicines – even if such an issue is done to the detriment of the actual future development of medicines – and those not willing to sacrifice Europe’s ability to innovate for the benefits of patients.

Over one-quarter of the EU working age population has a chronic disease, with 36% of EU adults over 65 years of age living with multiple chronic […]

On April 26th, the European Commission released its long-awaited review of the rules framing the pharmaceutical legislation. While highly anticipated, with objectives behind which every stakeholder […]

At Servier, we strive to develop medicines for the patients who need them. Putting patients first in our daily work is a commitment we take seriously […]

Stable manufacturing and supply chains in Europe are of essential importance to the day-to-day operations of pharmaceutical companies such as Servier and more critically to the […]

With only a few short months before the expected publication of the European Commission’s review of the General Pharmaceutical Legislation, the Orphan Medicinal Products Regulation and […]